English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives: Flow cytometry has been used for the evaluation of CD4 and CD8 counts and to monitor the status of the immunocompromised patients. This, in turn, has a major impact in modifying the treatment appropriately leading to the proper management of the patients in a timely manner. The AQUIOS CL Flow Cytometer introduces a new technology that forgoes sample preparation and staining by using a single Load and Go technology, thus allowing for rapid cell analysis TAT for CD4 and CD8 testing. We were previously using the Beckman FC-500 flow cytometry instrument, which required separate staining and lysing procedure and were time-consuming. To overcome this, we acquired and implemented the AQUIOS CL Flow Cytometer for an efficient and prompt reporting of CD4 and CD8 count. Methods: A sample is aspirated and dispensed from a closed tube, then dispensed into wells of a deep-well plate. Fluorochrome-labeled antibodies are added that bind to molecules on the cells that express specific antigens. As a part of quality assurance monitoring, retrospective split analysis was performed for 34 samples with the use of Aquios as well as FC-500. Method-to-method correlation was performed with the Bland-Altman method. Results: Our results demonstrated no statistically significance differences between the two instruments. However, TAT for the testing was significantly decreased with Aquios (20 minutes for the first specimen and then 2 minutes for each sequential specimen) as compared to FC-500 (1 hour), which significantly improved the reporting of results to the providers to implement treatment. Conclusion: The AQUIOS CL has significantly improved TAT for CD4 and CD8 testing, allowing for better patient care and treatment.

Advantages of the Use of AQUIOS CL Flow Cytometer in Evaluation of CD4 and CD8 in HIV Patients: CMCVAMC Experience